http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 13 May 2026 09:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Vicarious+Surgical+Demonstrates+Sustained+System+Performance+and+Complex+Hernia+Procedure+Workflows+in+Pre-Clinical+Setting/26482757.html <p align="left">WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced the successful completion of a full-day synthetic abdominal model lab demonstrating sustained system performance and continued procedural workflow progression for the Vicarious Surgical System.</p> <p align="left">During the lab, the Vicarious Surgical System operated fully draped for multiple hours while our CMO, Dr. Barry Greene, an experienced abdominal surgeon, performed back-to-back IPOM+ and robotic transabdominal preperitoneal (rTAPP) ventral hernia repair workflows. The lab was conducted using the Company’s integrated http://www.streetinsider.com/Press+Releases/Vicarious+Surgical+Demonstrates+Sustained+System+Performance+and+Complex+Hernia+Procedure+Workflows+in+Pre-Clinical+Setting/26482757.html Wed, 13 May 2026 09:00:00 -0400 A.10710336 O.02826370 O.50272814 RBOT http://www.streetinsider.com/Press+Releases/Vicarious+Surgical+Demonstrates+Sustained+System+Performance+and+Complex+Hernia+Procedure+Workflows+in+Pre-Clinical+Setting/26482757.html <p align="left">WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced the successful completion of a full-day synthetic abdominal model lab demonstrating sustained system performance and continued procedural workflow progression for the Vicarious Surgical System.</p> <p align="left">During the lab, the Vicarious Surgical System operated fully draped for multiple hours while our CMO, Dr. Barry Greene, an experienced abdominal surgeon, performed back-to-back IPOM+ and robotic transabdominal preperitoneal (rTAPP) ventral hernia repair workflows. The lab was conducted using the Company’s integrated http://www.streetinsider.com/Press+Releases/Vicarious+Surgical+Demonstrates+Sustained+System+Performance+and+Complex+Hernia+Procedure+Workflows+in+Pre-Clinical+Setting/26482757.html Wed, 13 May 2026 09:00:00 -0400 A.10710336 O.02826370 O.50272814 RBOT http://www.streetinsider.com/Press+Releases/Vicarious+Surgical+Demonstrates+Sustained+System+Performance+and+Complex+Hernia+Procedure+Workflows+in+Pre-Clinical+Setting/26482757.html <p align="left">WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced the successful completion of a full-day synthetic abdominal model lab demonstrating sustained system performance and continued procedural workflow progression for the Vicarious Surgical System.</p> <p align="left">During the lab, the Vicarious Surgical System operated fully draped for multiple hours while our CMO, Dr. Barry Greene, an experienced abdominal surgeon, performed back-to-back IPOM+ and robotic transabdominal preperitoneal (rTAPP) ventral hernia repair workflows. The lab was conducted using the Company’s integrated http://www.streetinsider.com/Press+Releases/Vicarious+Surgical+Demonstrates+Sustained+System+Performance+and+Complex+Hernia+Procedure+Workflows+in+Pre-Clinical+Setting/26482757.html Wed, 13 May 2026 09:00:00 -0400 A.10710336 O.02826370 O.50272814 RBOT http://www.streetinsider.com/Press+Releases/Vicarious+Surgical+Demonstrates+Sustained+System+Performance+and+Complex+Hernia+Procedure+Workflows+in+Pre-Clinical+Setting/26482757.html <p align="left">WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced the successful completion of a full-day synthetic abdominal model lab demonstrating sustained system performance and continued procedural workflow progression for the Vicarious Surgical System.</p> <p align="left">During the lab, the Vicarious Surgical System operated fully draped for multiple hours while our CMO, Dr. Barry Greene, an experienced abdominal surgeon, performed back-to-back IPOM+ and robotic transabdominal preperitoneal (rTAPP) ventral hernia repair workflows. The lab was conducted using the Company’s integrated http://www.streetinsider.com/Press+Releases/Vicarious+Surgical+Demonstrates+Sustained+System+Performance+and+Complex+Hernia+Procedure+Workflows+in+Pre-Clinical+Setting/26482757.html Wed, 13 May 2026 09:00:00 -0400 A.10710336 O.02826370 O.50272814 RBOT http://www.streetinsider.com/Globe+Newswire/Vicarious+Surgical+Demonstrates+Sustained+System+Performance+and+Complex+Hernia+Procedure+Workflows+in+Pre-Clinical+Setting/26482757.html <p align="left">WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced the successful completion of a full-day synthetic abdominal model lab demonstrating sustained system performance and continued procedural workflow progression for the Vicarious Surgical System.</p> <p align="left">During the lab, the Vicarious Surgical System operated fully draped for multiple hours while our CMO, Dr. Barry Greene, an experienced abdominal surgeon, performed back-to-back IPOM+ and robotic transabdominal preperitoneal (rTAPP) ventral hernia repair workflows. The lab was conducted using the Company’s integrated http://www.streetinsider.com/Globe+Newswire/Vicarious+Surgical+Demonstrates+Sustained+System+Performance+and+Complex+Hernia+Procedure+Workflows+in+Pre-Clinical+Setting/26482757.html Wed, 13 May 2026 09:00:00 -0400 A.10710336 O.02826370 O.50272814 RBOT http://www.streetinsider.com/Globe+Newswire/Vicarious+Surgical+Demonstrates+Sustained+System+Performance+and+Complex+Hernia+Procedure+Workflows+in+Pre-Clinical+Setting/26482757.html <p align="left">WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced the successful completion of a full-day synthetic abdominal model lab demonstrating sustained system performance and continued procedural workflow progression for the Vicarious Surgical System.</p> <p align="left">During the lab, the Vicarious Surgical System operated fully draped for multiple hours while our CMO, Dr. Barry Greene, an experienced abdominal surgeon, performed back-to-back IPOM+ and robotic transabdominal preperitoneal (rTAPP) ventral hernia repair workflows. The lab was conducted using the Company’s integrated http://www.streetinsider.com/Globe+Newswire/Vicarious+Surgical+Demonstrates+Sustained+System+Performance+and+Complex+Hernia+Procedure+Workflows+in+Pre-Clinical+Setting/26482757.html Wed, 13 May 2026 09:00:00 -0400 A.10710336 O.02826370 O.50272814 RBOT http://www.streetinsider.com/Globe+Newswire/Vicarious+Surgical+Demonstrates+Sustained+System+Performance+and+Complex+Hernia+Procedure+Workflows+in+Pre-Clinical+Setting/26482757.html <p align="left">WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced the successful completion of a full-day synthetic abdominal model lab demonstrating sustained system performance and continued procedural workflow progression for the Vicarious Surgical System.</p> <p align="left">During the lab, the Vicarious Surgical System operated fully draped for multiple hours while our CMO, Dr. Barry Greene, an experienced abdominal surgeon, performed back-to-back IPOM+ and robotic transabdominal preperitoneal (rTAPP) ventral hernia repair workflows. The lab was conducted using the Company’s integrated http://www.streetinsider.com/Globe+Newswire/Vicarious+Surgical+Demonstrates+Sustained+System+Performance+and+Complex+Hernia+Procedure+Workflows+in+Pre-Clinical+Setting/26482757.html Wed, 13 May 2026 09:00:00 -0400 A.10710336 O.02826370 O.50272814 RBOT http://www.streetinsider.com/Globe+Newswire/Vicarious+Surgical+Demonstrates+Sustained+System+Performance+and+Complex+Hernia+Procedure+Workflows+in+Pre-Clinical+Setting/26482757.html <p align="left">WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced the successful completion of a full-day synthetic abdominal model lab demonstrating sustained system performance and continued procedural workflow progression for the Vicarious Surgical System.</p> <p align="left">During the lab, the Vicarious Surgical System operated fully draped for multiple hours while our CMO, Dr. Barry Greene, an experienced abdominal surgeon, performed back-to-back IPOM+ and robotic transabdominal preperitoneal (rTAPP) ventral hernia repair workflows. The lab was conducted using the Company’s integrated http://www.streetinsider.com/Globe+Newswire/Vicarious+Surgical+Demonstrates+Sustained+System+Performance+and+Complex+Hernia+Procedure+Workflows+in+Pre-Clinical+Setting/26482757.html Wed, 13 May 2026 09:00:00 -0400 A.10710336 O.02826370 O.50272814 RBOT http://www.streetinsider.com/Earnings/Vicarious+Surgical+Inc.+%28RBOT%29+Misses+Q1+EPS+by+103c/26401764.html <p>Vicarious Surgical Inc. (NYSE: RBOT) reported Q1 EPS of ($1.03).</p><p>For earnings history and earnings-related data on Vicarious Surgical Inc. (RBOT) <a href="http://www.streetinsider.com/ec_earnings.php?q=RBOT">click here</a>.</p> http://www.streetinsider.com/Earnings/Vicarious+Surgical+Inc.+%28RBOT%29+Misses+Q1+EPS+by+103c/26401764.html Thu, 30 Apr 2026 08:59:42 -0400 RBOT http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Vicarious+Surgical+Inc.+++For%3A+Mar+31/26401553.html si-local-file:///var/storage/secattach/20260430/26401553.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Vicarious+Surgical+Inc.+++For%3A+Mar+31/26401553.html Thu, 30 Apr 2026 08:35:00 -0400 O.50272814 RBOT http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Vicarious+Surgical+Inc.+++For%3A+Mar+31/26401553.html si-local-file:///var/storage/secattach/20260430/26401553.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Vicarious+Surgical+Inc.+++For%3A+Mar+31/26401553.html Thu, 30 Apr 2026 08:35:00 -0400 O.50272814 RBOT http://www.streetinsider.com/Press+Releases/Vicarious+Surgical+Reports+First+Quarter+2026+Financial+Results/26401452.html <p align="left">WALTHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (OTCQB: RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Financial Results</strong></p> <ul><li style="text-align:justify;">Total operating expenses were $7.5 million in the first quarter of 2026, compared to $15.7 million in the first quarter of 2025, a decrease of 52%.</li></ul> <ul><li style="text-align:justify;">Research and development expenses in the first quarter of 2026 were $5.0 million, compared to $9.4 million http://www.streetinsider.com/Press+Releases/Vicarious+Surgical+Reports+First+Quarter+2026+Financial+Results/26401452.html Thu, 30 Apr 2026 08:30:00 -0400 A.10710336 O.02826370 O.50272814 RBOT http://www.streetinsider.com/Press+Releases/Vicarious+Surgical+Reports+First+Quarter+2026+Financial+Results/26401452.html <p align="left">WALTHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (OTCQB: RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Financial Results</strong></p> <ul><li style="text-align:justify;">Total operating expenses were $7.5 million in the first quarter of 2026, compared to $15.7 million in the first quarter of 2025, a decrease of 52%.</li></ul> <ul><li style="text-align:justify;">Research and development expenses in the first quarter of 2026 were $5.0 million, compared to $9.4 million http://www.streetinsider.com/Press+Releases/Vicarious+Surgical+Reports+First+Quarter+2026+Financial+Results/26401452.html Thu, 30 Apr 2026 08:30:00 -0400 A.10710336 O.02826370 O.50272814 RBOT http://www.streetinsider.com/Press+Releases/Vicarious+Surgical+Reports+First+Quarter+2026+Financial+Results/26401452.html <p align="left">WALTHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (OTCQB: RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Financial Results</strong></p> <ul><li style="text-align:justify;">Total operating expenses were $7.5 million in the first quarter of 2026, compared to $15.7 million in the first quarter of 2025, a decrease of 52%.</li></ul> <ul><li style="text-align:justify;">Research and development expenses in the first quarter of 2026 were $5.0 million, compared to $9.4 million http://www.streetinsider.com/Press+Releases/Vicarious+Surgical+Reports+First+Quarter+2026+Financial+Results/26401452.html Thu, 30 Apr 2026 08:30:00 -0400 A.10710336 O.02826370 O.50272814 RBOT http://www.streetinsider.com/Press+Releases/Vicarious+Surgical+Reports+First+Quarter+2026+Financial+Results/26401452.html <p align="left">WALTHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (OTCQB: RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Financial Results</strong></p> <ul><li style="text-align:justify;">Total operating expenses were $7.5 million in the first quarter of 2026, compared to $15.7 million in the first quarter of 2025, a decrease of 52%.</li></ul> <ul><li style="text-align:justify;">Research and development expenses in the first quarter of 2026 were $5.0 million, compared to $9.4 million http://www.streetinsider.com/Press+Releases/Vicarious+Surgical+Reports+First+Quarter+2026+Financial+Results/26401452.html Thu, 30 Apr 2026 08:30:00 -0400 A.10710336 O.02826370 O.50272814 RBOT http://www.streetinsider.com/Globe+Newswire/Vicarious+Surgical+Reports+First+Quarter+2026+Financial+Results/26401452.html <p align="left">WALTHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (OTCQB: RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Financial Results</strong></p> <ul><li style="text-align:justify;">Total operating expenses were $7.5 million in the first quarter of 2026, compared to $15.7 million in the first quarter of 2025, a decrease of 52%.</li></ul> <ul><li style="text-align:justify;">Research and development expenses in the first quarter of 2026 were $5.0 million, compared to $9.4 million http://www.streetinsider.com/Globe+Newswire/Vicarious+Surgical+Reports+First+Quarter+2026+Financial+Results/26401452.html Thu, 30 Apr 2026 08:30:00 -0400 A.10710336 O.02826370 O.50272814 RBOT http://www.streetinsider.com/Globe+Newswire/Vicarious+Surgical+Reports+First+Quarter+2026+Financial+Results/26401452.html <p align="left">WALTHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (OTCQB: RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Financial Results</strong></p> <ul><li style="text-align:justify;">Total operating expenses were $7.5 million in the first quarter of 2026, compared to $15.7 million in the first quarter of 2025, a decrease of 52%.</li></ul> <ul><li style="text-align:justify;">Research and development expenses in the first quarter of 2026 were $5.0 million, compared to $9.4 million http://www.streetinsider.com/Globe+Newswire/Vicarious+Surgical+Reports+First+Quarter+2026+Financial+Results/26401452.html Thu, 30 Apr 2026 08:30:00 -0400 A.10710336 O.02826370 O.50272814 RBOT http://www.streetinsider.com/Globe+Newswire/Vicarious+Surgical+Reports+First+Quarter+2026+Financial+Results/26401452.html <p align="left">WALTHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (OTCQB: RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Financial Results</strong></p> <ul><li style="text-align:justify;">Total operating expenses were $7.5 million in the first quarter of 2026, compared to $15.7 million in the first quarter of 2025, a decrease of 52%.</li></ul> <ul><li style="text-align:justify;">Research and development expenses in the first quarter of 2026 were $5.0 million, compared to $9.4 million http://www.streetinsider.com/Globe+Newswire/Vicarious+Surgical+Reports+First+Quarter+2026+Financial+Results/26401452.html Thu, 30 Apr 2026 08:30:00 -0400 A.10710336 O.02826370 O.50272814 RBOT http://www.streetinsider.com/Globe+Newswire/Vicarious+Surgical+Reports+First+Quarter+2026+Financial+Results/26401452.html <p align="left">WALTHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (OTCQB: RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2026.</p> <p align="justify"><strong>First Quarter 2026 Financial Results</strong></p> <ul><li style="text-align:justify;">Total operating expenses were $7.5 million in the first quarter of 2026, compared to $15.7 million in the first quarter of 2025, a decrease of 52%.</li></ul> <ul><li style="text-align:justify;">Research and development expenses in the first quarter of 2026 were $5.0 million, compared to $9.4 million http://www.streetinsider.com/Globe+Newswire/Vicarious+Surgical+Reports+First+Quarter+2026+Financial+Results/26401452.html Thu, 30 Apr 2026 08:30:00 -0400 A.10710336 O.02826370 O.50272814 RBOT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vicarious+Surgical+Inc.+++For%3A+Apr+08/26289690.html si-local-file:///var/storage/secattach/20260408/26289690.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vicarious+Surgical+Inc.+++For%3A+Apr+08/26289690.html Wed, 08 Apr 2026 16:30:00 -0400 O.50272814 RBOT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vicarious+Surgical+Inc.+++For%3A+Apr+08/26289690.html si-local-file:///var/storage/secattach/20260408/26289690.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vicarious+Surgical+Inc.+++For%3A+Apr+08/26289690.html Wed, 08 Apr 2026 16:30:00 -0400 O.50272814 RBOT http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Vicarious+Surgical+Inc.++++++++++++++++Filed+by%3A+Innovation+Endeavors+III+LP/26277835.html si-local-file:///var/storage/secattach/20260406/26277835.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Vicarious+Surgical+Inc.++++++++++++++++Filed+by%3A+Innovation+Endeavors+III+LP/26277835.html Mon, 06 Apr 2026 19:01:00 -0400 O.50272814 RBOT http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Vicarious+Surgical+Inc.++++++++++++++++Filed+by%3A+Innovation+Endeavors+III+LP/26277835.html si-local-file:///var/storage/secattach/20260406/26277835.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Vicarious+Surgical+Inc.++++++++++++++++Filed+by%3A+Innovation+Endeavors+III+LP/26277835.html Mon, 06 Apr 2026 19:01:00 -0400 O.50272814 RBOT http://www.streetinsider.com/Corporate+News/Vicarious+Surgical+completes+testing+of+surgical+instrument+suite/26240649.html <p>Vicarious Surgical Inc. (OTCQB: RBOT) announced the completion of integrated benchtop testing for its full suite of surgical instruments designed for ventral hernia repair procedures. The testing evaluated three core instruments: needle drivers, fenestrated graspers, and monopolar scissors, all designed for use with the company's surgical robotics system.</p><p>The monopolar scissors demonstrated motion and mechanical cutting capabilities following the company's automated calibration process. During testing, instrument and camera sensors remained stable with no degradation in video or motion quality when exposed to monopolar electrosurgical energy.</p><p>"This milestone represents an important step in systematically de-risking our system as we advance toward design freeze http://www.streetinsider.com/Corporate+News/Vicarious+Surgical+completes+testing+of+surgical+instrument+suite/26240649.html Mon, 30 Mar 2026 16:15:52 -0400 RBOT http://www.streetinsider.com/Press+Releases/Vicarious+Surgical+Completes+Integrated+Benchtop+Testing+of+Full+Surgical+Instrument+Suite+for+Ventral+Hernia+Repair/26240636.html <p>WALTHAM, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced the successful completion of initial integrated benchtop testing for its full suite of surgical instruments, required for its anticipated first clinical indication of ventral hernia repair, marking an important step toward design validation, clinical readiness, and the Company’s targeted design freeze milestone.</p> <p>This milestone represents the first system-level performance evaluation of the Company&apos;s three core instruments: needle drivers, fenestrated graspers, and monopolar scissors, each of which is designed for http://www.streetinsider.com/Press+Releases/Vicarious+Surgical+Completes+Integrated+Benchtop+Testing+of+Full+Surgical+Instrument+Suite+for+Ventral+Hernia+Repair/26240636.html Mon, 30 Mar 2026 16:15:00 -0400 A.10710336 O.02826370 O.50272814 RBOT